A 1331852 is a high affinity and selective Bcl-xL inhibitor (Ki <0.01 nM), also inhibits Bcl-W, Bcl-2, and Mcl-1 (Ki values are 4, 6 and 142 nM, respectively). A 1331852 inhibits Bcl-xL-dependent Molt 4 acute lymphoblastic leukemia cell growth
in vitro
(EC50 = 6 nM). It enhances antitumor effects of Docetaxel (Cat. No. 4056) and Venetoclax (Cat. No. 6960) in xenograft models of breast and lung cancer. A 1331852 also induces apoptosis in and clears senescent biliary epithelial cells (BECs), and induces apoptosis in xenograft models of EBV-associated T- and natural killer cell lymphoma.
Caractéristiques techniques
| Marque | Tocris Bioscience |
|---|
| Réf. B-LABO | BL-RE-124528 |
|---|
| Réf. fabricant | 18716816 |
|---|
| Nom chimique ou matériau | 6-[8-[(2-Benzothiazolylamino)carbonyl]-3,4-dihydro-2(1 H)-isoquinolinyl]-3-[5-methyl-1-(tricyclo[3.3.1.13,7 ]dec-1-ylmethyl)-1 H-pyrazol-4-yl]-2-pyridinecarboxylic acid |
|---|
| CAS | 1430844-80-6 |
|---|
| Quantité | 10 mg |
|---|
| Cible | Bcl-xL |
|---|
| Formule moléculaire | C<sub>38</sub>H<sub>38</sub>N<sub>6</sub>O<sub>3</sub>S |
|---|
| Pureté | 0.98 |
|---|
Une question, une configuration particulière ?
Contactez-nous pour un devis.
